LIQUIDIA CORP (LQDA)

Commit To Purchase Liquidia Corp At $7.50, Earn 15.5% Annualized Using Options

Commit To Buy Liquidia Corp At $10, Earn 28% Annualized Using Options

Notable Thursday Option Activity: ANF, LQDA, ALLY

Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference

Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference

MORRISVILLE, N.C., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs,...

Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder

Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder

On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman LitigationOn March 29, Judge Bates denied United Therapeutics’ motion...

Notable Wednesday Option Activity: GOOGL, LQDA, WCC

Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approvalFederal Circuit rejected request by United Therapeutics for rehearing...

Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024

Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024

MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.

Noteworthy Friday Option Activity: FSLR, SWAV, LQDA

Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress

Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress

MORRISVILLE, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today announced that the Company will...

Liquidia stock slips as FDA delays review for Yutrepia

The U.S. FDA has extended the review period for Liquidia Corporation's (LQDA) request to add a new indication for its drug-device combination Yutrepia. Read more here.

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder

MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug...

Notable Tuesday Option Activity: TRGP, RC, LQDA

Interesting LQDA Put And Call Options For March 15th

Liquidia announces updates to operations leadership (NASDAQ:LQDA)

Liquidia (LQDA) announces promotions to its operations leadership, including Michael Kaseta as new COO/CFO, ahead of YUTREPIA launch.

Liquidia Corporation Announces Updates to Operations Leadership

Liquidia Corporation Announces Updates to Operations Leadership

MORRISVILLE, N.C., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions...

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests...